Vardenafil is indicated exclusively for the management of Erectile Dysfunction (ED) in adult men. This condition is characterized by the inability to attain or sustain a penile erection suitable for satisfactory sexual activity.

The medication is utilized in clinical scenarios where the difficulties in achieving or maintaining an erection are linked to physical factors. The purpose of this treatment is to support the physiological process necessary for achieving and keeping an erection upon sexual stimulation. It is important to note that the drug does not increase sexual desire and requires the presence of stimulation to be effective.

Vardenafil may be used to address difficulties in:

• Achieving an erection
• Maintaining erection firmness
• Improving overall functional capacity

---

Quick Fact: Relief for Erectile Difficulties

Levitra (vardenafil) is officially indicated for use only in adult men (18 years and older) diagnosed with erectile dysfunction.

Contraindications: Who Must Not Use Levitra

The medicine is strictly contraindicated for patients using any form of nitrates or nitric oxide donors (due to severe hypotensive risk), or guanylate cyclase stimulators (e.g., riociguat). Use is also prohibited in patients with known hypersensitivity to vardenafil, severe hepatic impairment (Child-Pugh C), or those undergoing renal dialysis. Contraindications also include a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) or certain hereditary retinal degenerative disorders.

Restricted and Conditional Use

Age and Organ Function: Pediatric use is not indicated. A lower 5 mg starting dose should be considered for men aged 65 years and older. Patients with moderate hepatic impairment (Child-Pugh B) or severe renal impairment should also use a lower starting dose.

Special Conditions: Caution is advised for men whose underlying cardiovascular status makes sexual activity inadvisable (e.g., recent stroke, unstable angina, or severe hypotension). Use is also restricted for those with conditions predisposing to priapism or anatomical penile deformation (e.g., Peyronie's disease).

Interactions with other medicines and products

Levitra's official interaction profile is characterized by two primary mechanisms: additive hypotensive effects and metabolic clearance modification.

Contraindicated Combinations

Co-administration is strictly prohibited with Nitrates and Nitric Oxide Donors (in any form) due to the risk of potentiating hypotensive effects. Concomitant use with the guanylate cyclase stimulator Riociguat is also contraindicated. Additionally, the co-administration of Vardenafil with potent CYP3A4 inhibitors (e.g., Ritonavir, Indinavir) is contraindicated [FDA label].

Pharmacokinetic Interactions

Vardenafil is predominantly cleared by the liver enzyme CYP3A4. Inhibitors of this enzyme reduce Vardenafil clearance, causing a significant increase in systemic exposure. This includes potent inhibitors (Ritonavir, Indinavir, high-dose Ketoconazole/Itraconazole) and moderate inhibitors (e.g., Erythromycin, Clarithromycin). A maximum dose restriction of 2.5 mg every 72 hours is required when co-administered with Ritonavir.

Other Documented Interactions

• Alpha-Blockers: Vardenafil can have an additive effect on blood pressure when co-administered with alpha-blockers, such as Tamsulosin, increasing the risk of symptomatic hypotension.
• QT-Prolonging Agents: Potential exists for an additive effect on QT interval prolongation with certain antiarrhythmics.
• Grapefruit Juice: Consumption is expected to increase Vardenafil plasma concentrations due to CYP3A4 inhibition and should be avoided.

How Levitra Works: Pharmacodynamic Mechanism

The mechanism of vardenafil is defined by its action as a highly selective competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), a molecular target concentrated in the smooth muscle cells of the penile vasculature. By binding to PDE5, the drug prevents the breakdown of the key second messenger, Cyclic Guanosine Monophosphate (cGMP). This preservation of cGMP is the essential molecular step governing the ensuing physiological cascade.

Vardenafil operates by modulating the natural Nitric Oxide (NO)-cGMP signaling cascade, though its effect is conditional and only begins following sexual stimulation, as NO release is required to initially synthesize cGMP. This action extends the duration of the cGMP signal, resulting in enhanced penile vasodilation. The sustained accumulation of cGMP causes the smooth muscle of the penile arteries to relax. This modulation of peripheral vascular tone allows blood flow to dramatically increase into the corpus cavernosum and results in the primary physiological consequence of increased penile turgidity and rigidity. This localized hemodynamic change is the final step linking the molecular mechanism to the observable functional effect.

How Levitra is Used: Administration Guidelines

Levitra (Vardenafil) is strictly an oral medication. Usage instructions define the administration method, dosing schedule, and consumption context, which are established for correct use.

Standard Dosing and Frequency

The medicine is taken as needed, meaning prior to sexual activity, and is not taken more than once every 24 hours. Dosing regimens are generally characterized by the following parameters:

Guideline	Film-Coated Tablet	Orally Disintegrating Tablet (ODT)
Recommended Starting Dose	10 mg	10 mg
Typical Dose Range	5 mg to 20 mg	Not applicable (fixed 10 mg dose)
Maximum Dose	20 mg	10 mg

Administration Timing and Context

For the film-coated tablet, the dose is typically taken approximately 25 to 60 minutes before anticipated sexual activity. The drug requires the presence of sexual stimulation to facilitate an erection.

The film-coated tablet may be taken with or without food, but taking it with a high-fat meal may delay the onset of action. The ODT formulation is taken by placing it on the tongue and allowing it to disintegrate; it does not require water.

Population-Specific Use

Specific dosage modifications exist for certain populations. For example, a lower starting dose of 5 mg for the film-coated tablet is generally noted for older adults (65 years and over) and for individuals with mild to moderate hepatic impairment. The maximum recommended dose may also be lower in these specific cases.

Research evidence / Overview of studies for Levitra

---

Evidence for use in Erectile Dysfunction

The foundational evidence for Vardenafil (Levitra) comes primarily from multiple Randomized Controlled Trials (RCTs). These short-term, controlled studies were used in research exploring how symptoms change over time for adult men diagnosed with Erectile Dysfunction (ED). The design involved comparing men who received Vardenafil against men who received an inactive substance, or placebo, which contributed to the regulatory assessment of Vardenafil. Studies explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, using patient-reported questionnaires.

The research examined how patients reported their ability to achieve and maintain an erection sufficient for sexual activity. Studies reported measurements of specific changes in erectile function, and findings describe patterns observed in the studies. For example, trials monitored patients' reports of successful penetration and successful maintenance of an erection until the completion of intercourse, which are key outcomes reflecting daily functioning or activity level.

Measuring Outcomes in Pivotal Trials

To evaluate the evidence, researchers used established instruments accepted by regulatory bodies. These included the International Index of Erectile Function (IIEF), which generates a score reflecting a patient's overall erectile function. Studies also used specific questions from the Sexual Encounter Profile (SEP), such as the question about the ability to maintain erection. Findings help contextualize how patients reported their experience during the study period, and the majority of men in the trials receiving Vardenafil reported positive responses on their erections, as recorded by the Global Assessment Question (GAQ).

---

Evidence in Specific Comorbidity Groups

Studies also explored Vardenafil's research patterns in men who have ED alongside other medical conditions, or comorbidities. Dedicated research examined populations with diabetes mellitus, a condition characterized by functional limitations, to see how symptoms evolved in this subgroup. Another specialized area of research examined men who had undergone a radical prostatectomy.

Findings were observed in some studies within these specific groups, and the results reflect the specific conditions under which they were conducted. Research provides context but not individual predictions, and the studies helped show what has been observed so far in men facing these particular health challenges alongside ED.

---

Long-Term Research and Follow-up Duration

Most of the primary efficacy research focused on short-term symptom patterns, with many pivotal RCTs monitoring patient responses over a defined time interval of about 12 weeks. Some study protocols allowed for treatment extensions, and data was collected for up to six months or even a year in some research scenarios, allowing studies to monitor outcomes related to systemic or functional imbalance over slightly longer periods.

Despite these extensions, research exploring long-term outcomes is limited in scope. This means that while research provides insight into short-term changes, there is limited data available from long-term observational settings.

---

Evidence in Older Adults and Other Populations

Vardenafil was evaluated in studies that included a wide age range of adult men. Specific data analysis was conducted for older men (ge 65 years) to explore how symptom patterns evolved in this age group, which may be marked by functional limitations.

However, research is ongoing, and data for certain groups remain insufficient. For instance, data for certain groups remain insufficient, and data are still emerging for men with more severe underlying health issues, such as those with severe renal or hepatic impairment. Follow-up durations were limited for some of these specific patient groups.

---

Understanding Research Gaps and Uncertainties

Research provides context but not individual predictions, and the overall evidence landscape has several areas where further data would be beneficial. One key research limitation frame is that research exploring long-term outcomes is limited in scope, as the most robust data covers only the first few months of use.

Furthermore, data for certain groups remain insufficient, particularly for men with severe renal or hepatic impairment, meaning the certainty remains low for outcomes in these specific clinical situations. Most studies primarily examined Vardenafil against a placebo, meaning comparative evidence against other medications is not established by the core research. These evidence gaps help contextualize what is known—and what is still uncertain—about this medication.

Key Studies & References

1. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports

Common questions about Levitra (FAQ)

Q: What's the difference between the film-coated tablet and the ODT form?

The film-coated tablet can be taken either with or without food. In contrast, the Orally Disintegrating Tablet (ODT) is designed to be placed on the tongue to dissolve quickly without needing water. Official product information notes that, for certain formulations, the ODT may lead to slightly higher levels of the active ingredient in the bloodstream compared to the film-coated tablet.

---

Q: How long does Levitra stay in your system?

Studies indicate that vardenafil, the active ingredient, and its primary breakdown product have an elimination half-life of approximately 4 to 5 hours. The half-life of a drug is a measure used to track how quickly the substance leaves the body, with vardenafil being predominantly eliminated through feces.

---

Q: How does Levitra lead to an erection, starting from the sexual stimulation step?

The drug's action is conditional on sexual stimulation, which facilitates the body's natural release of nitric oxide (NO). Regulatory documents state that the drug then acts by inhibiting a specific enzyme (PDE5), which allows a natural erection-promoting substance (cGMP) to accumulate. This process causes smooth muscles to relax, enhancing blood flow to the penis.

---

Q: How quickly does Levitra start working (onset of action)?

According to official product information, the maximum concentration of the drug in the blood is typically reached about one hour after taking a dose when fasted, though the time may vary. The therapeutic effect of the medicine requires the presence of sexual stimulation to occur.

---

Q: Can women or children take Levitra?

Official prescribing information indicates that this medicine is only for the treatment of erectile dysfunction in adult men. Its use is not recommended in women, including those who are pregnant or breastfeeding, and it is not indicated for use in children.

---

Q: What should I do if I miss a dose?

Since the medication is taken 'as needed,' prior to sexual activity, and not on a regular schedule, the concept of a 'missed dose' does not apply. The medicine is only intended to be taken before anticipated sexual activity.

---

Q: What happens if I take more than the maximum dose?

Taking doses higher than the maximum recommended amount increases the risk of side effects and can increase their severity. Regulatory reports from studies involving high doses noted an increased occurrence of issues like visual disturbances, dizziness, and a risk of priapism (a prolonged erection). If more than the maximum recommended dose is taken, it is important to seek immediate medical attention, as overdose may increase the severity of side effects.

---

Q: What is the typical time frame of long-term use for Levitra?

The clinical trials submitted for regulatory assessment primarily focused on short-term patterns, typically around 12 weeks, with some follow-up data extending up to one year. The duration of use is a clinical matter that is determined based on individual patient circumstances and health status.

How to Store and Dispose of Levitra (Vardenafil)

The storage and disposal of Levitra must adhere strictly to regulatory requirements to maintain product stability and safety.

️ Storage Requirements

Levitra must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from environmental damage by keeping it away from heat, moisture, and direct light, and it must not be frozen. It is mandatory to store the medicine in a closed container and out of the reach of children.

️ Disposal Instructions

Outdated or no longer needed medicine must not be kept. For proper disposal, patients should ask a healthcare professional or pharmacist for guidance. Unused product must be disposed of according to local regulations to ensure environmental protection.